Methyl 2-hexyl-2-methyloctanoate | 88016-20-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Methyl 2-hexyl-2-methyloctanoate
• CAS: 88016-20-0
• 化学式: C₁₆H₃₂O₂
• 分子量: 256.429
• InChiKey: PFROVMCGWZAHFW-UHFFFAOYSA-N

物化性质

• 沸点：
  287.7±8.0 °C(Predicted)
• 密度：
  0.8652 g/cm3(Temp: 20 °C; mixture of isomers)

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  18
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-己烯 、 丙酸甲酯 生成 Methyl 2-hexyl-2-methyloctanoate
  参考文献：
  名称：

  TERENTEV, A. B.;IKONNIKOV, N. S.;DOSTOVALOVA, V. I., IZV. AN CCCP. CEP. XIM., 1983, N 7, 1546-1551

  摘要：

  DOI：

文献信息

• Telomerization of 1-hexene with methyl chloroacetate and methyl propionate
  作者：A. B. Terent'ev、N. S. Ikonnikov、V. I. Dostovalova

  DOI：10.1007/bf00954345

  日期：1983.7
• TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Genentech, Inc.

  公开号：US20170226132A1

  公开（公告）日：2017-08-10

  Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.
• CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
  申请人：Intellikine LLC

  公开号：US20170281614A1

  公开（公告）日：2017-10-05

  Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
• TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS
  申请人：Infinity Pharmaceuticals, Inc.

  公开号：US20180015093A1

  公开（公告）日：2018-01-18

  Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating cancers or hematologic disorders.
• 10-(DI(PHENYL)METHYL)-4-HYDROXY-8,9,9A,10-TETRAHYDRO-7H-PYRROLO[1 ',2':4,5]PYRAZINO[1,2-B]PYRIDAZINE-3,5-DIONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE ORTHOMYXOVIRUS REPLICATION FOR TREATING INFLUENZA
  申请人：Novartis AG

  公开号：US20200407366A1

  公开（公告）日：2020-12-31

  The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.